Lung cancer screening with spiral CT: Baseline results of the randomized DANTE trial
Introduction
Lung cancer is the most frequent malignancy in the adult population of the western world, and carries a severe prognosis with 5-year survival rates in the range of 7–15% [1]. In only 16% of the cases is the disease still localized at the time of diagnosis [2].
Given its high incidence and the existence of an easily identifiable high-risk population, e.g. smokers and former smokers [3], lung cancer appears to be an ideal candidate for screening programs. As with any other form of cancer screening, the basic assumption is that the detection of early-stage tumours in asymptomatic subjects should prevent the eventual appearance of advanced incurable disease at a later time, thus reducing mortality.
Unfortunately, the randomized trials on lung cancer screening carried out in the seventies and eighties [4], [5], [6], [7] were unable to demonstrate any mortality reduction in spite of the detection of an increased number of resectable, early-stage cases. However, all of those studies employed chest X-rays (CXR) and sputum cytology for early diagnosis.
With the advent of new technology and the introduction of low-dose spiral computed tomography (LDCT), new hopes have been raised. In Japan, mass screening programs with spiral CT have been active since the mid-nineties [8], [9], [10], and many uncontrolled studies were launched in the following years in western countries [11], [12], [13], [14], [15], [16].
All of these studies demonstrated that screening with spiral CT allows the detection of a high proportion of early-stage lung cancers. Additionally, the I-ELCAP group has reported a 10-year survival rate of 92% for resected stage I patients and of 80% for the whole series [17].
Nonetheless, the potential of screening with spiral CT not only for detecting patients with early-stage disease but especially for reducing mortality has yet to be demonstrated and carefully weighed against its costs and expected screening-related morbidity. Furthermore, the cost-effectiveness of lung cancer screening with spiral CT is controversial, as it depends on a number of conditions [18], [19], [20].
To help answer the question, in March 2001 we launched a randomized study (the DANTE Trial) comparing clinical review versus spiral CT at annual intervals for 4 years. We herewith present the baseline findings of this prospective randomized study on the early diagnosis of lung cancer.
Section snippets
Study design
DANTE is a prospective randomized trial exploring the effects of screening with spiral CT on lung cancer-specific mortality and on the stage distribution and resectability rates in a high-risk population. The prevalence of a set of biomarkers in sputum and blood samples is also being assessed.
The research has been conducted by the Istituto Clinico Humanitas, Milan, Italy, starting in March 2001. In 2005, two more centres of the same hospital network, Humanitas Gavazzeni Hospital, Bergamo, and
Results
Accrual was opened in March 2001 and closed in February 2006. In this period, 2564 subjects underwent the baseline medical assessment, and 92 of them were considered ineligible. The most common causes for non-eligibility were a history of neoplasia, insufficient exposure to cigarette smoking or advanced comorbidity.
As shown in Table 3 and Fig. 1, 2472 subjects (1276 in the spiral CT arm and 1196 controls) were finally randomized: 2033 (83%) at the Istituto Clinico Humanitas Hospital, Milan, 269
Discussion
High resection rates and 5-year survival have been reported for incidental and especially for screening-detected stage I lung cancer patients [17], [21], [22], [23]. These data are in contrast with the low resectability rates and dismal prognosis of symptom-detected cases [2]. Consequently, screening of high-risk subjects has become an attractive option. However, concerns were raised as early as 2000 [24], [25] about the potential biases of uncontrolled screening studies. The overdiagnosis
Conflict of interest statement
None.
Acknowledgements
The Authors wish to thank Mrs. Penelope Ann Taylor for her kind assistance and advice in the preparation of the manuscript.
References (39)
- et al.
The changing epidemiology of lung cancer in Europe
Lung Cancer
(2003) - et al.
Screening for early lung cancer: results of the Memorial–Sloan Kettering study in New York
Chest
(1984) - et al.
Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies
Chest
(2002) - et al.
Early Lung Cancer Action Project: overall design and findings from baseline screening
Lancet
(1999) - et al.
Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results
Lancet
(2003) - et al.
Screening for lung cancer with CT: a preliminary cost-effectiveness analysis
Chest
(2002) - et al.
Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting
Lung Cancer
(2005) - et al.
Prognosis of patients with lung cancer found in a single chest radiograph screening
Chest
(1998) - et al.
The effect of surgical treatment on survival from early lung cancer. Implications for screening
Chest
(1992) - et al.
Survival of patients surgically treated for stage I lung cancer
J Thorac Cardiovasc Surg
(1981)
Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs. chest radiograph: the Lung Screening Study of the National Cancer Institute
Chest
ITALUNG-CT screening for lung cancer: preliminary results [abstract]
Lung Cancer
Thoracic surgical operations in patients enrolled in a computed tomographic screening trial
J Thorac Cardiovasc Surg
Multiple primary lung cancers
J Thorac Cardiovasc Surg
Patterns of absolute risk of lung cancer mortality in former smokers
J Natl Cancer Inst
Lung cancer screening: the Mayo program
J Occup Med
Survival and mortality from lung cancer in a screened population: the Johns Hopkins study
Chest
Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia
Int J Cancer
Cited by (174)
Lung cancer screening with low dose computed tomography : a systematic review
2021, Revue des Maladies RespiratoiresLung Cancer Screening
2021, Encyclopedia of Respiratory Medicine, Second EditionLung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
2021, Journal of Thoracic OncologyBaseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation
2020, Lung CancerCitation Excerpt :Overall prevalence of lung cancer was 2.5 %, comparable to UK based studies where prevalence has ranged from 1.9 % to 3.0 % [3,5,8]. Of those diagnosed with lung cancer in the West London pilot, 58.6 % had stage I lung cancer, lower than the first round of the NELSON trial [16], but comparable to, or higher than, other European screening trials [17–19]. By contrast, only 15 % of lung cancers identified in the general population in England are stage I at diagnosis [20].
- 1
Members of the DANTE Study Group, Gianluigi Ravasi (MD), Maurizio Infante (MD), Umberto Cariboni (MD), Marco Alloisio (MD), Alberto Testori (MD), Matteo Incarbone (MD), Valentina Errico (MD), Edoardo Bottoni (MD), Diego Ruzzante (MD), Francesco Inzirillo (MD), Thoracic Surgery Department, Istituto Clinico Humanitas, Rozzano, Milan, Italy. Fabio Lutman (MD), Giorgio Brambilla (MD), Pasquala Ragucci, Radiology Department, Istituto Clinico Humanitas, Rozzano, Milan, Italy. Arturo Chiti (MD), Gianluigi Ciocia (MD), Nuclear Medicine Department, Istituto Clinico Humanitas, Rozzano, Milan, Italy. Anna Destro (PhD), Paolo Bianchi (PhD), Giovanna Gribaudi (PhD), Massimo Roncalli (MD, PhD), Pathology Deparment, Istituto Clinico Humanitas, Rozzano, Milan, Italy. Silvio Cavuto (DSc, Consultant Statistician), Italian Association for the Fight against Cancer, Milan, Italy. Michele Tedeschi (MD), Emanuela Morenghi (PhD), Clinical Research Department, Istituto Clinico Humanitas, Rozzano, Milan, Italy. Giuseppe Chiesa (MD), Eliseo Passera (MD), Alberto Meroni (MD), Giovanni Guanella (MD), Adriano Rizzi (MD), Thoracic Surgery Department, Humanitas-Gavazzeni, Bergamo, Italy. Enzo Angeli (MD), Bertacchi Giacomo (MD), Radiology Department, Humanitas-Gavazzeni, Bergamo, Italy. Aranzulla Giuseppe (MD), Pane Francesco (MD), Radiology Department, Humanitas–Catania Oncology Centre, Italy. Maurizio Chiarenza (MD), Michele Caruso (MD), Oncology Department, Humanitas–Catania Oncology Centre (Centro Catanese di Oncologia), Italy.